Head-to-Head Analysis: BioForce Nanosciences (OTCMKTS:BFNH) vs. Seer (NASDAQ:SEER)

[ad_1]


BioForce Nanosciences (OTCMKTS:BFNH – Get Rating) and Seer (NASDAQ:SEER – Get Rating) are both small-cap medical companies, but which is the better stock? We’ll compare the two companies based on earnings strength, risk, analyst recommendations, dividends, valuation, profitability, and institutional ownership.

Profitability

This table compares the net margins, return on equity and return on assets of BioForce Nanosciences and Seer.

Net margins Return on equity return on assets
BioForce Nanosciences N / A N / A -2,538.94%
Seeing -794.43% -15.44% -14.71%

Volatility and risk

BioForce Nanosciences has a beta of -1.49, which means its stock price is 249% less volatile than the S&P 500. Comparatively, Seer has a beta of 3.13, which means its stock price is 213% more volatile than the S&P 500.

Analyst Notes

This is a summary of recent valuations and target prices for BioForce Nanosciences and Seer, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
BioForce Nanosciences 0 0 0 0 N / A
Seeing 0 1 1 0 2.50

Seer has a consensus target price of $21.00, indicating a potential upside of 163.82%. Given Seer’s higher possible upside, analysts clearly believe that Seer is more favorable than BioForce Nanosciences.

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of BioForce Nanosciences and Seer.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
BioForce Nanosciences $20,000.00 1,527.20 -$500,000.00 ($0.01) -200.00
Seeing $6.62 million 75.08 -$71.17 million ($1.27) -6.27

BioForce Nanosciences has higher revenue, but lower revenue than Seer. BioForce Nanosciences trades at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.9% of Seer shares are held by institutional investors. 39.5% of the shares of BioForce Nanosciences are held by insiders of the company. By comparison, 28.9% of Seer’s stock is held by company insiders. Strong institutional ownership indicates that hedge funds, large fund managers, and endowments believe a stock is poised for long-term growth.

BioForce Nanosciences Company Profile (Get a rating)

BioForce Nanosciences Holdings, Inc. is focused on providing natural vitamins, minerals, other nutritional supplements, powders and beverages for people of different age groups. The company offers private label products with distributors and manufacturing suppliers. It sells its nutritional supplements to retailers, sporting goods retailers, supermarkets and mass merchandisers under the BioForce Eclipse brand, as well as online and through telemarketing. The company is based in Virginia Beach, Virginia.

Company Profile (Get a rating)

Seer, Inc., a life sciences company, engages in the development and commercialization of products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that includes consumables, automation instrumentation and software that enables researchers to conduct proteomics studies in therapeutic and diagnostic research and clinical trials. The Company intends to sell its products for research purposes, which covers academic institutions, life sciences and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.



Get news and reviews for BioForce Nanosciences Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for BioForce Nanosciences and related companies with MarketBeat.com’s FREE daily newsletter.

[ad_2]
Source link

Comments are closed.